// App-Quantinova.ai

P42 : Use of trametinib, a MEK1 inhibitor, to treat Erdheim Chester disease (ECD)

Researchers

Presenter

  • Hoda Alkoky

Principal Investigators

  • Talha Munir

  • Frances Borg

Medical Centers

  • Paediatric, Southend University Hospital NHS Trust, Southend, UNITED KINGDOM

  • Rheumatology, Leeds, Essex, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Inflammatory Arthritis

  • Diabetes

Biomarkers

  • Dual specificity mitogen-activated protein kinase kinase 1

  • Ecdysoneless

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Methotrexate

  • Prednisolone

  • Trametinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved